Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 45 AND POTASSIUM CHLORIDE 0 15 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 45 AND POTASSIUM CHLORIDE 0 15 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides exogenous glucose for cellular energy metabolism and corrects electrolyte imbalances. Sodium and chloride maintain osmotic pressure and acid-base balance. Potassium is essential for nerve conduction, muscle contraction, and intracellular enzyme function.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous infusion: 1000-2000 mL/day as maintenance, adjusted based on fluid, electrolyte, and energy needs.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Potassium: approximately 1-1.5 hours (distribution phase) with a terminal elimination half-life of about 8-12 hours in renal impairment. Dextrose: effectively infinite as it is metabolized; sodium and chloride follow body regulation with no defined half-life.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Components are eliminated via renal excretion: glucose is metabolized and excreted as CO2 and water; sodium, chloride, and potassium are excreted renally with over 90% of infused potassium appearing in urine within 24 hours.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte